Psychopharmacology

Credit

Handouts

Speaker

David Dadiomov, PharmD, BCPP Related seminars and products

---

David Dadiomov, PharmD, BCPP, is an assistant professor of clinical pharmacy in the Titus Family Department of Clinical Pharmacy at the USC Mann School of Pharmacy and Pharmaceutical Sciences.

He holds board certification in psychiatric pharmacy and serves as the director of the PGY2 Psychiatric Pharmacy Residency Program. He has led, co-led and conducted extensive research on opioid use disorders among vulnerable populations, prevalence and distribution of high-risk prescription opioid use, therapeutic drug monitoring, treatment-resistant psychiatric conditions and more. Dr. Dadiomov practices as a clinical pharmacy specialist in addiction and psychiatry at the Complex Care Clinic of the Los Angeles County Department of Health Services, one of the largest of its kind in the United States.

Dr. Dadiomov’s teaching approach is case focused, practical for any clinical setting, interactive and evidence supported. His expertise has been shared with experienced clinicians, graduate students and advanced level students. Dr. Dadiomov is the recipient of multiple awards for clinical excellence, teaching and clinical innovation and has presented, authored and co-authored multiple peer-reviewed journal articles, book chapters, and scientific presentations.

 

Speaker Disclosures:
Financial: Dr. David Dadiomov has employment relationships with the University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California Psychiatry and behavioral Sciences Medical Residency, and the Los Angeles County Department of Health Services. He previously received a speaking honorarium from Eli Lilly. Dr. Dadiomov receives grants from the 2024 SC CTSI Standard Pilot Grand Program, the USC Good Neighbors Grant Program, the Southern California Clinical and Translational Sciences Institute, and the Foundation for Opioid Response Efforts. He receives a speaking honorarium and recording royalties from Psychotherapy Networker and PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. David Dadiomov is a member of the American Society of Addiction Medicine, the American Association of Psychiatric Pharmacists, the American College of Clinical Pharmacy, and the American Society of Health-System Pharmacists. He is a reviewer for several publications, for a complete list contact PESI.com.

Additional Info

Program Information

Access never expires for this product.

For a more detailed outline that includes times or durations of time, if needed, please contact cepesi@pesi.com.

Objectives

1. Discuss the proper role of mental health professionals who treat clients receiving both psychotherapeutic medications and psychotherapy.
2. Describe specific ethical issues and resolutions related to communicating with clients and prescribing professionals about psychotropic medications.
3. Explain the neurotransmitter systems and neuroanatomy underlying the biological basis for mental disorders and pharmacotherapy.
4. Identify the major classes of drugs used to treat mental disorders and which mental disorders are appropriately treated with each class of drugs.
5. Describe adverse effects and drug reactions of the commonly prescribed psychotropic medications and when to alert the prescriber about them.
6. Analyze the role that half-life plays in the efficacy of insomnia medications prescribed for clients and how it may affect behavioral interventions.

Outline

MEDS 101

• Case study
• Reasons to be knowledgeable about psychiatric medications
• Lessons from other disciplines
• Pharmacy
• Nursing
• Ethics guidelines
• The common questions clients have about their medications
• Handling differences of opinion between yourself and a prescribing professional

GENERAL OVERVIEW OF THE NERVOUS SYSTEM

• Organization of the nervous system
• Structure of the neuron
• Communication between neurons
• How medicines interact with the nervous system

DEPRESSION MEDICATIONS

• Neurobiology
• SSRIs and SNRIs
• Mechanism of action
• Benefits and adverse reactions
• Medications in these categories
• Case study

ANXIETY DISORDER MEDICATIONS

• DSM-5® anxiety categories
• Deconstructionist approach taken by prescribers
• Neurobiology
• SSRIs and Benzodiazepines
• Mechanism of action
• Benefits and adverse reactions
• Medications in these categories
• Case study

BIPOLAR MEDICATIONS

• Monotherapy
• Lithium, anticonvulsants, and 2nd generation antipsychotics
• Mechanism of action
• Benefits and adverse reactions
• Medications in these categories
• Case study

ADHD MEDICATIONS

• Neurobiology
• Methylphenidate and amphetamine
• Mechanism of action
• Delivery systems
• Benefits and adverse reactions
• Medications in these categories
• Case study

ANTIPSYCHOTIC MEDICATIONS

• Psychosis symptoms
• Neurobiology
• 1st and 2nd generation
• Antipsychotics
• Mechanism of action
• Benefits and adverse reactions
• Medications in these categories
• Case study

INSOMNIA MEDICATIONS

• Causes and treatments for insomnia
• Medications for insomnia
• Half-life
• Benefits and adverse reactions
• Case study

LIMITATIONS OF THE RESEARCH & POTENTIAL RISKS

Target Audience

• Counselors
• Social Workers
• Psychologists
• Psychotherapists
• Case Managers
• Art Therapists
• Marriage & Family Therapists
• Nurses
• Nurse Practitioners
• Clinical Nurse Specialists
• Substance Use Disorders Counselors
• Occupational Therapists
• Physicians
• Occupational Therapy Assistants
• Other Mental Health & Health Care Professionals